The present invention relates to polymorphs and solvates of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027), processes for their preparation, and to pharmaceutical compositions comprising them.
|
0. 30. A solid form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 19.8 and 29.0.
0. 45. A solid form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 15.8, 18.9 and 26.2.
0. 41. A solid form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 15.7, 17.4, and 18.1.
0. 49. A solid form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 11.7, 19.1, 23.4, and 24.1.
0. 53. A solid form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 14.8 and 22.0, wherein the solid form is a dioxane solvate.
0. 57. A solid form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 22.3 and 25.5, wherein the solid form is a chloroform solvate.
16. A process for the preparation of phase I form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine comprising the step of heating crystalline forms phase ii, phase iii and/or phase iv of this compound at a temperature between 140° C. and 170° C.
0. 61. A solid form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine selected from the group consisting of:
(a) a polymorphic phase I form having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 19.8 and 29.0;
(b) a polymorphic phase ii form having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 15.7, 17.4, and 18.1;
(c) a polymorphic phase iii form having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 15.8, 18.9, and 26.2;
(d) a polymorphic phase iv form having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 11.7, 19.1, 23.4, and 24.1;
(e) a dioxane solvate having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 14.8 and 22.0; and
(f) a chloroform solvate having an x-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 22.3 and 25.5.
1. A solid polymorphic or solvated form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine selected from the group consisting of:
a) a polymorphic phase I form having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 5.9, 8.1, 11.3, 11.7, 14.2, 15.1, 15.8, 16.3, 16.8, 17.8, 18.1, 18.6, 19.8, 20.9, 21.9, 22.8, 23.0, 23.2, 23.6, 23.9, 24.3, 25.0, 25.1, 28.0, 28.3, 28.6, 29.0, 29.2, 30.7, and 30.9;
b) a polymorphic phase ii form having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 5.776, 11.629, 14.558, 15.737, 15.891, 16.420, 16.740, 17.441, 17.635, 18.056, 18.219, 19.232, 19.712, 20.140, 20.685, 21.135, 21.889, 22.108, 22.478, 22.763, 23.219, 23.454, 23.782, 24.689, 25.065, and 25.671;
c) a polymorphic phase iii form having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 5.437, 5.714, 10.918, 11.546, 12.704, 13.344, 13.984, 14.505, 15.606, 15.824, 16.164, 16.646, 17.333, 17.837, 18.719, 18.878, 19.236, 19.533, 20.142, 20.689, 21.337, 22.008, 22.929, 23.596, 24.748, 25.064, 25.207, 25.737, and 26.148;
d) a polymorphic phase iv form, preferably having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 5.805, 11.685, 15.559, 15.804, 16.397, 16.879, 17.357, 17.465, 17.621, 19.112, 19.435, 19.923, 21.224, 21.987, 22.167, 22.412, 2.852, 23.059, 23.359, 23.855, 24.092, 25.722, 26.054, 26.649, and 27.780;
e) a dioxane solvate having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 4.734, 9.317, 11.390, 13.614, 14.290, 14.815, 16.211, 16.432, 16.782, 17.741, 18.056, 18.329, 18.724, 19.070, 19.494, 20.436, 20.762, 21.587, 22.000, 22.935, 23.084, 23.551, 23.891, 24.721, and 25.078; and
f) a chloroform solvate having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 11.370, 13.396, 14.048, 15.010, 15.303, 16.117, 16.804, 17.040, 17.830, 18.029, 18.661, 18.859, 19.190, 20.150, 20.434, 21.424, 22.279, 22.871, 23.449, 23.918, 24.343, 24.709, 24.820, 25.459, and 26.199;
with the 2θ values being obtained using copper radiation (CuKα1 1.54060 Å).
2. A process for the preparation of the polymorphic phase I form as defined in
a) dissolving 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride in a suitable solvent, and
b) evaporating the solvent.
3. The process according to
4. A process for the preparation of the polymorphic phase I form as defined in
5. The process according to
6. The process according to
8. A process for the preparation of the polymorphic phase I form as defined in
9. The process according to
10. A process for the preparation of the polymorphic phase ii form as defined in
a) dissolving the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in water in the presence of catalytic amounts of poly(vinyl alcohol), and
b) evaporating the water.
11. A process for the preparation of the polymorphic phase iii form as defined in
a) dissolving the hydrochloride salt of 4-[(2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in water or acetone in the presence of catalytic amounts of poly(ethylene glycol), and
b) evaporating the water or the acetone;
or comprising:
a) dissolving the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in water in the presence of catalytic amounts of poly(ethylene glycol), and
b) adding diisopropyl ether as antisolvent.
12. A process for the preparation of the polymorphic phase iv form as defined in
a) dissolving the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in chloroform in the presence of catalytic amounts of a polymer selected from the group consisting of: polyvinyl pyrrolidone, poly(acrylic acid), polypropylene, poly(styrene-co-divinylbenzene), poly(tetrafluoroethylene), poly(vinyl alcohol), polyacrylamide and poly(methyl methacrilate methacrylate), and
b) adding diisopropyl ether as antisolvent.
13. A process for the preparation of the dioxane solvate as defined in
a) solvent drop grinding comprising:
a) charging the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine together with catalytic quantities of dioxane to a ball mill container; and
b) grinding; or
b) crystallization from a hot saturated solution of dioxane.
14. A process for the preparation of the chloroform solvate as defined in
a) dissolving the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in chloroform in the presence of catalytic amounts of a polymer selected from the group consisting of poly(ethylene glycol), polyvinyl pyrrolidone, poly(acrylic acid), nylon 6/6, polypropylene, poly(tetrafluoroethylene), poly(vinyl acetate), poly(vinyl alcohol), polyacrylamide and polysulfone; and
b) either evaporating the chloroform or crystallizing in a hot saturated solution of chloroform.
15. A process for the preparation of the phase I form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine of
18. The solid polymorphic or solvated form of
a polymorphic phase I form having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 5.9, 8.1, 11.3, 11.7, 14.2, 15.1, 15.8, 16.3, 16.8, 17.8, 18.1, 18.6, 19.8, 20.9, 21.9, 22.8, 23.0, 23.2, 23.6, 23.9, 24.3, 25.0, 25.1, 28.0, 28.3, 28.6, 29.0, 29.2, 30.7, and 30.9,
with the 28 values being obtained using copper radiation (CUKα1 1.54060 Å).
19. The solid polymorphic or solvated form of
a polymorphic phase ii form having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 5.776, 11.629, 14.558, 15.737, 15.891, 16.420, 16.740, 17.441, 17.635, 18.056, 18.219, 19.232, 19.712, 20.140, 20.685, 21.135, 21.889, 22.108, 22.478, 22.763, 23.219, 23.454, 23.782, 24.689, 25.065, and 25.671,
with the 2θ values being obtained using copper radiation (CuKα1 1.54060 Å).
20. The solid polymorphic or solvated form of
a polymorphic phase iii form having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 5.437, 5.714, 10.918, 11.546, 12.704, 13.344, 13.984, 14.505, 15.606, 15.824, 16.164, 16.646, 17.333, 17.837, 18.719, 18.878, 19.236, 19.533, 20.142, 20.689, 21.337, 22.008, 22.929, 23.596, 24.748, 25.064, 25.207, 25.737, and 26.148,
with the 2θ values being obtained using copper radiation (CuKα1 1.54060 Å).
21. The solid polymorphic or solvated form of
a polymorphic phase iv form, preferably having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 5.805, 11.685, 15.559, 15.804, 16.397, 16.879, 17.357, 17.465, 17.621, 19.112, 19.435, 19.923, 21.224, 21.987, 22.167, 22.412, 2.852, 23.059, 23.359, 23.855, 24.092, 25.722, 26.054, 26.649, and 27.780,
with the 2θ values being obtained using copper radiation (CuKα1 1.54060 Å).
22. The solid polymorphic or solvated form of
a dioxane solvate having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 4.734, 9.317, 11.390, 13.614, 14.290, 14.815, 16.211, 16.432, 16.782, 17.741, 18.056, 18.329, 18.724, 19.070, 19.494, 20.436, 20.762, 21.587, 22.000, 22.935, 23.084, 23.551, 23.891, 24.721, and 25.078,
with the 2θ values being obtained using copper radiation (CuKα1 1.54060 Å).
23. The solid polymorphic or solvated form of
a) a chloroform solvate having a x-ray powder diffraction pattern showing characteristic peaks at a reflection angle [2θ in degrees] of about 11.370, 13.396, 14.048, 15.010, 15.303, 16.117, 16.804, 17.040, 17.830, 18.029, 18.661, 18.859, 19.190, 20.150, 20.434, 21.424, 22.279, 22.871, 23.449, 23.918, 24.343, 24.709, 24.820, 25.459, and 26.199,
with the 2θ values being obtained using copper radiation (CuKα1 1.54060 Å).
0. 31. The solid form of claim 30, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 16.3, 17.8, 21.9, and 22.8.
0. 32. The solid form of claim 30, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 5.9, 8.1, 11.3, 11.7, 14.2, 15.1, 15.8, 16.8, 18.1, 18.6, 20.9, 23.0, 23.2, 23.6, 23.9, 24.3, 25.0, 25.1, 28.0, 28.3, 28.6, 29.2, 30.7, and 30.9.
0. 33. A process for the preparation of the solid form as defined in claim 30, comprising; a) dissolving 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride in a suitable solvent, and b) evaporating the solvent.
0. 34. The process according to claim 33, wherein 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride is dissolved at a temperature ranging from room temperature to 120° C. and/or the solvent is evaporated at a temperature ranging from −21° C. to 60° C.
0. 35. A process for the preparation of the solid form as defined in claim 30, comprising mixing a solution comprising 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride with a suitable antisolvent.
0. 36. The process according to claim 35, wherein the mixing is performed at a temperature ranging from room temperature to 90° C.
0. 37. The process according to claim 35, wherein the mixing is performed by a liquid-liquid diffusion or a gas-liquid diffusion.
0. 38. The process according to claim 33, further comprising adding water to the solution.
0. 39. A process for the preparation of the solid form as defined in claim 30, comprising preparing a suspension comprising 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride.
0. 40. The process according to claim 39, wherein the suspension is maintained at a temperature ranging from room temperature to 80° C.
0. 42. The solid form of claim 41, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 17.6 and 22.1.
0. 43. The solid form of claim 41, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 5.8, 11.6, 14.56, 15.9, 16.4, 16.7, 17.4, 18.2, 19.2, 19.7, 20.1, 20.7, 21.1, 21.9, 22.5, 22.8, 23.2, 23.5, 23.8, 24.7, 25.1, and 25.7.
0. 44. A process for the preparation of the solid form as defined in claim 41, comprising: a) dissolving the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in water in the presence of catalytic amounts of poly(vinyl alcohol), and b) evaporating the water.
0. 46. The solid form of claim 45, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 16.2, 17.8, 18.7, and 23.6.
0. 47. The solid form of claim 45, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 5.4, 5.7, 10.9, 11.5, 12.7, 13.3, 14.0, 14.5, 15.6, 16.6, 17.3, 19.2, 19.5, 20.1, 20.7, 21.3, 22.0, 22.9, 24.7, 25.1, 25.2, and 25.7.
0. 48. A process for the preparation of the solid form as defined in claim 45, comprising: a) dissolving the hydrochloride salt of 4-[(2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in water or acetone in the presence of catalytic amounts of poly(ethylene glycol), and b) evaporating the water or the acetone; or comprising: a) dissolving the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in water in the presence of catalytic amounts of poly(ethylene glycol), and b) adding diisopropyl ether as antisolvent.
0. 50. The solid form of claim 49, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 15.6, 16.4, 16.9, 17.6, and 22.0.
0. 51. The solid form of claim 49, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 5.8, 15.8, 17.4, 17.5, 19.4, 19.9, 21.2, 22.2, 22.4, 22.9, 23.1, 23.9, 24.1, 25.7, 26.1, 26.6, and 27.8.
0. 52. A process for the preparation of the solid form as defined in claim 49, comprising: a) dissolving the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in chloroform in the presence of catalytic amounts of a polymer selected from the group consisting of: polyvinyl pyrrolidone, poly(acrylic acid), polypropylene, poly(styrene-co-divinylbenzene), poly(tetrafluoroethylene), poly(vinyl alcohol), polyacrylamide and poly(methyl methacrylate), and b) adding diisopropyl ether as antisolvent.
0. 54. The solid form of claim 53, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 18.7 and 19.1.
0. 55. The solid form of claim 53, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 4.7, 9.3, 11.4, 13.6, 14.3, 16.2, 16.4, 16.8, 17.7, 18.1, 18.3, 19.5, 20.4, 20.8, 21.6, 22.9, 23.1, 23.6, 23.9, 24.7, and 25.1.
0. 56. A process for the preparation of the solid form as defined in claim 53, comprising: a) solvent drop grinding comprising: a) charging the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine together with catalytic quantities of dioxane to a ball mill container; and b) grinding; or b) crystallization from a hot saturated solution of dioxane.
0. 58. The solid form of claim 57, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 11.4, 15.0, and 26.2.
0. 59. The solid form of claim 57, having an x-ray powder diffraction pattern further comprising a peak, in terms of 2-theta, at about 13.4, 14.0, 15.3, 16.1, 16.8, 17.0, 17.8, 18.0, 18.7, 18.9, 19.2, 20.2, 20.4, 21.4, 22.9, 23.4, 23.9, 24.3, 24.7, and 24.8.
0. 60. A process for the preparation of the solid form as defined in claim 57, comprising: a) dissolving the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in chloroform in the presence of catalytic amounts of a polymer selected from the group consisting of poly(ethylene glycol), polyvinyl pyrrolidone, poly(acrylic acid), nylon 6/6, polypropylene, poly(tetrafluoroethylene), poly(vinyl acetate), poly(vinyl alcohol), polyacrylamide and polysulfone; and b) either evaporating the chloroform or crystallizing in a hot saturated solution of chloroform.
0. 62. A process for the preparation of the polymorphic phase I form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine of claim 61 comprising heating the polymorphic phase ii form, polymorphic phase iii form, polymorphic phase iv form, dioxane solvate or chloroform solvate.
0. 63. A process for the preparation of phase I form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine of claim 61, comprising the step of heating crystalline forms phase ii, phase iii and/or phase iv of this compound at a temperature between 140° C. and 170° C.
0. 64. A pharmaceutical composition comprising the solid form defined in claim 30.
0. 65. A pharmaceutical composition comprising the solid form defined in claim 41.
0. 66. A pharmaceutical composition comprising the solid form defined in claim 45.
0. 67. A pharmaceutical composition comprising the solid form defined in claim 49.
0. 68. A pharmaceutical composition comprising the solid form defined in claim 53.
0. 69. A pharmaceutical composition comprising the solid form defined in claim 57.
0. 70. The solid form of claim 30, wherein the solid form is polymorphic phase I form.
0. 71. The solid form of claim 41, wherein the solid form is polymorphic phase ii form.
0. 72. The solid form of claim 45, wherein the solid form is polymorphic phase iii form.
0. 73. The solid form of claim 49, wherein the solid form is polymorphic phase iv form.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a §371 national stage of PCT International Application No. PCT/EP2011/051630, filed Feb. 4, 2011, claiming priority of European Patent Application Nos. EP 10 382 226.8, filed Aug. 9, 2010 and EP 10 382 025.4, filed Feb. 4, 2010, the contents of each of which are hereby incorporated by reference into this application.
The present invention relates to polymorphs and solvates of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027), processes for their preparation, and to pharmaceutical compositions comprising them.
The search for new therapeutic agents has been greatly aided in recent years by better understanding of the structure of proteins and other biomolecules associated with target diseases. One important class of these proteins is the sigma (σ) receptor, a cell surface receptor of the central nervous system (CNS) which may be related to the dysphoric, hallucinogenic and cardiac stimulant effects of opioids. From studies of the biology and function of sigma receptors, evidence has been presented that sigma receptor ligands may be useful in the treatment of psychosis and movement disorders such as dystonia and tardive dyskinesia, and motor disturbances associated with Huntington's chorea or Tourette's syndrome and in Parkinson's disease (Walker, J. M. et al, Pharmacological Reviews, 1990, 42, 355). It has been reported that the known sigma receptor ligand rimazole clinically shows effects in the treatment of psychosis (Snyder, S. H., Largent, B. L. J. Neuropsychiatry 1989, 1, 7). The sigma binding sites have preferential affinity for the dextrorotatory isomers of certain opiate benzomorphans, such as (+)SKF 10047, (+)cyclazocine, and (+)pentazocine and also for some narcoleptics such as haloperidol.
The sigma receptor has at least two subtypes, which may be discriminated by stereoselective isomers of these pharmacoactive drugs. SKF 10047 has nanomolar affinity for the sigma 1 (σ-1) site, and has micromolar affinity for the sigma 2 (σ-2) site. Haloperidol has similar affinities for both subtypes. Endogenous sigma ligands are not known, although progesterone has been suggested to be one of them. Possible sigma-site-mediated drug effects include modulation of glutamate receptor function, neurotransmitter response, neuroprotection, behavior, and cognition (Quirion, R. et al. Trends Pharmacol. Sci., 1992, 13:85-86). Most studies have implied that sigma binding sites (receptors) are plasmalemmal elements of the signal transduction cascade. Drugs reported to be selective sigma ligands have been evaluated as antipsychotics (Hanner, M. et al. Proc. Natl. Acad. Sci., 1996, 93:8072-8077). The existence of sigma receptors in the CNS, immune and endocrine systems have suggested a likelihood that it may serve as link between the three systems.
In view of the potential therapeutic applications of agonists or antagonists of the sigma receptor, a great effort has been directed to find selective ligands. Thus, the prior art discloses different sigma receptor ligands. 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine is one of such promising sigma receptor ligands. The compound and its synthesis are disclosed and claimed in WO2006/021462.
4-[2-[([5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine is a highly selective sigma-1 (σ-1) receptor antagonist. It has displayed strong analgesic activity in the treatment and prevention of chronic and acute pain, and particularly, neuropathic pain. The compound has a molecular weight 337.42 uma. The structural formula of the compound is:
##STR00001##
The solid state physical properties of a pharmaceutical compound can be influenced by the conditions under which the compound is obtained in solid form. Solid state physical properties include, for example, the flowability of the milled solid which affects the ease with which the compound is handled during processing into a pharmaceutical product. Another important solid state property of a pharmaceutical compound is its rate of dissolution in aqueous fluid. The rate of dissolution of an active ingredient in a patient's stomach fluid can have therapeutic consequences because it imposes an upper limit on the rate at which an orally administered active ingredient can reach the blood. The solid-state form of a compound may also affect its solubility, bioavailability, behavior on compaction, stability, or its electrostatic nature.
Polymorphism is the property of some molecules and molecular complexes to assume more than one crystalline or amorphous form in the solid state. In general, polymorphism is caused by the ability of the molecule of a substance to change its conformation or to form different inter molecular and intramolecular interactions, particularly hydrogen bonds, which is reflected in different atom arrangements in the crystal lattices of different polymorphs. Accordingly, polymorphs are distinct solids sharing the same molecular Formula, having distinct advantageous and/or disadvantageous physical properties compared to other forms in the polymorph family.
The term “solvate” refers to any solid form of a given compound in which said compound is bonded by a non-covalent bond to molecule(s) of solvent (normally a polar solvent).
The discovery of new crystalline polymorphic or amorphous forms of a pharmaceutical compound provides an opportunity to improve the physical or performance characteristics of a pharmaceutical product in that it enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristics.
Therefore, there is still a need in the art for additional forms of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine to carry out its pharmaceutical development and release its potential, and facilitate the preparation of better formulations of this active pharmaceutical ingredient. In this regard, different morphological forms of the compound may have widely different properties such as, for example, enhanced thermodynamic stability, higher purity or improved bioavailability (e.g. better absorption, dissolution patterns) and could either become intermediates for other forms or provide in themselves a still better formulation of this active pharmaceutical ingredient. Specific compound forms could also facilitate the manufacturing (e.g. enhanced flowability), handling and storage (e.g. non-hygroscopic, long shelf life) of the compound formulations or allow the use of a lower dose of the therapeutic agent, thus decreasing its potential side effects. Thus it is important to find such forms, having desirable properties for pharmaceutical use.
The inventors of the present invention have surprisingly found and demonstrated that new solid forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027) may achieve one or more of the above mentioned objectives. The novel polymorphic and solvated forms of P027 herein disclosed are fairly stable over the time and have good flow and dissolution characteristics. Particularly, a novel and highly stable crystalline form of the P027 compound (phase I form) provides advantageous production, handling, storage and therapeutic properties. Further, some of the new solid forms of P027 may be useful as intermediates for other useful forms such as the crystalline phase I form of P027.
Thus, the present invention relates to polymorphic forms and solvates of P027, to their use and to several processes for their preparation.
The hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027) can be prepared by contacting a solution of the base with hydrochloric acid. The P027 compound has a molecular weight 373.88 uma, a pKa of 6.73 and a melting point of 194.2° C. The compound is very soluble in water and freely soluble in methanol, 1N hydrochloric acid and dimethyl sulphoxide. It is sparingly soluble in ethanol, slightly soluble in acetone and practically insoluble in ethyl acetate and in 1N sodium hydroxide. The product exhibits a better dissolution and absorption profile in vivo than its related base.
In one embodiment, the present invention is directed to a solid polymorphic or solvated form of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine.
Preferably, said solid form is selected from the group consisting of:
TABLE 1
List of selected peaks obtained by powder
X-Ray diffraction of phase II
Angle (2θ)
d value (Å)
Intensity (%)
5.776
15.28888
30.2
11.629
7.60368
8.3
14.558
6.07960
4.4
15.737
5.62658
73.1
15.891
5.57256
37.3
16.420
5.39408
14.1
16.740
5.29166
12.7
17.441
5.08075
23.7
17.635
5.02527
100.0
18.056
4.90895
44.8
18.219
4.86548
23.3
19.232
4.61143
22.9
19.712
4.50004
4.4
20.140
4.40556
2.8
20.685
4.29064
4.3
21.135
4.20016
7.6
21.889
4.05717
33.0
22.108
4.01757
46.8
22.478
3.95233
8.8
22.763
3.90336
14.1
23.219
3.82779
13.5
23.454
3.78998
21.3
23.782
3.73840
12.6
24.689
3.60310
15.6
25.065
3.54983
10.6
25.671
3.46750
13.7
TABLE 2
List of selected peaks obtained by powder
X-Ray diffraction of phase III
Angle (2θ)
d value (Å)
Intensity (%)
5.437
16.24165
14.9
5.714
15.45508
31.2
10.918
8.09724
1.9
11.546
7.65777
3.4
12.704
6.96243
2.3
13.344
6.63006
7.3
13.984
6.32777
6.0
14.505
6.10193
3.7
15.606
5.67363
24.1
15.824
5.59613
61.7
16.164
5.47909
40.3
16.646
5.32137
5.1
17.333
5.11195
8.3
17.837
4.96880
80.1
18.719
4.73663
62.4
18.878
4.69703
38.3
19.236
4.61037
10.2
19.533
4.54088
25.1
20.142
4.40496
20.3
20.689
4.28973
15.8
21.337
4.16103
4.2
22.008
4.03562
13.9
22.929
3.87545
19.6
23.596
3.76747
100.0
24.748
3.59457
10.1
25.064
3.55008
35.7
25.207
3.53024
47.7
25.737
3.45874
25.5
26.148
3.40521
66.9
TABLE 3
List of selected peaks obtained by powder
X-Ray diffraction of phase IV
Angle (2θ)
d value (Å)
Intensity (%)
5.805
15.21150
51.5
11.685
7.56709
30.4
15.559
5.69074
84.9
15.804
5.60321
7.1
16.397
5.40173
49.5
16.879
5.24838
47.7
17.357
5.10514
39.2
17.465
5.07372
42.4
17.621
5.02921
66.8
19.112
4.64012
100.0
19.435
4.56373
3.8
19.923
4.45292
16.1
21.224
4.18278
10.9
21.987
4.03934
83.5
22.167
4.00707
45.4
22.412
3.96379
33.8
22.852
3.88840
18.0
23.059
3.85401
14.4
23.359
3.80517
61.8
23.855
3.72720
13.6
24.092
3.69105
29.7
25.722
3.46066
16.4
26.054
3.41730
10.8
26.649
3.34237
16.3
27.780
3.20885
4.2
TABLE 4
List of selected peaks obtained by powder
X-Ray diffraction of the dioxane solvate
Angle (2θ)
d value (Å)
Intensity (%)
4.734
18.65133
12.1
9.317
9.48417
17.2
11.390
7.76280
14.5
13.614
6.49913
6.8
14.290
6.19322
6.6
14.815
5.97468
47.7
16.211
5.46334
17.2
16.432
5.39027
15.0
16.782
5.27852
5.4
17.741
4.99534
4.4
18.056
4.90904
9.2
18.329
4.83643
9.2
18.724
4.73540
82.7
19.070
4.65016
44.1
19.494
4.55001
4.5
20.436
4.34235
21.4
20.762
4.27483
18.4
21.587
4.11339
26.7
22.000
4.03705
100.0
22.935
3.87457
24.2
23.084
3.84979
22.3
23.551
3.77450
14.0
23.891
3.72152
5.6
24.721
3.59850
3.6
25.078
3.54803
13.2
TABLE 5
List of selected peaks obtained by powder
X-Ray diffraction of the chloroform solvate
Angle (2θ)
d value (Å)
Intensity (%)
11.370
7.77642
10.0
13.396
6.60439
0.9
14.048
6.29920
1.1
15.010
5.89751
33.5
15.303
5.78539
4.0
16.117
5.49492
4.2
16.804
5.27165
1.5
17.040
5.19923
6.6
17.830
4.97065
2.1
18.029
4.91633
8.4
18.661
4.75106
11.3
18.859
4.70167
7.1
19.190
4.62136
2.9
20.150
4.40334
3.1
20.434
4.34278
1.1
21.424
4.14416
2.5
22.279
3.98707
100.0
22.871
3.88527
16.8
23.449
3.79074
9.1
23.918
3.71738
0.9
24.343
3.65347
3.1
24.709
3.60019
4.6
24.820
3.58439
1.8
25.459
3.49576
16.4
26.199
3.39873
7.6
According to another embodiment, the crystalline P027 phase I form of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride according to the present invention has a monoclinic unit cell with the following approximate dimensions:
a=29.4(3)Å
b=11.7(11)Å
c=11.0(10)Å
α=90°
β=91.3 (2)
γ=90°
The preparation of the above polymorphic and solvated forms represents additional embodiments of the present invention.
The P027 phase I form can be prepared by crystallizing the P027 compound in various solvents by means of various techniques such as: solvent evaporation at varying temperatures, crystallization from hot saturated solutions, crystallization by antisolvent addition, crystallization by antisolvent diffusion, crystallization from water and solvents mixtures and the preparation of suspensions.
P027 phase II form may be obtained in polymer induced crystallizations by solvent evaporation.
P027 phase III form may be obtained in polymer induced crystallizations either by solvent evaporation or by crystallization by antisolvent addition.
P027 phase IV form may be obtained in polymer induced crystallizations by crystallization by antisolvent addition.
P027 dioxane solvate may be obtained by solvent drop grinding in dioxane or by crystallization from a hot saturated solution of dioxane.
P027 chloroform solvate may be obtained in polymer induced crystallizations either by solvent (chloroform) evaporation or by crystallization from hot saturated solutions of chloroform.
Another embodiment of the present invention includes the transformation of crystalline forms phase II, phase III and phase IV above into a more stable polymorphic form such as P027 phase I form.
Another embodiment of the present invention includes the transformation of a solvate of P027, preferably chloroform solvate, into a more stable polymorphic form such as phase I form.
A further embodiment of the present invention includes pharmaceutical compositions comprising at least one of the forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine above-mentioned, particularly P027 phase I, P027 phase II. P027 phase III. P027 phase IV. P027 chloroform solvate and P027 dioxane solvate.
These aspects and preferred embodiments thereof are additionally also defined in the claims.
The inventors of the present invention have found novel solid forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027) which provide advantageous production, handling, storage and therapeutic properties. These compounds have advantages due to the fact that they are solids, what simplifies isolation, purification and handling. In addition, the phase I form of this compound is highly stable and can be formulated and administered providing stable compositions and good pharmacological properties. Additionally, the new forms of P027 may be used for obtaining other forms, such as crystalline phase I form of P027.
As used herein, the term “about” means a slight variation of the value specified, preferably within 10 percent of the value specified. Nevertheless, the term “about” can mean a higher tolerance of variation depending on for instance the experimental technique used. Said variations of a specified value are understood by the skilled person and are within the context of the present invention. Further, to provide a more concise description, some of the quantitative expressions given herein are not qualified with the term “about”. It is understood that, whether the term “about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and/or measurement conditions for such given value.
As used herein, “room temperature” or its abbreviation “rt” is taken to mean 20 to 25° C.
The new forms of P027 herein disclosed were characterized by powder X-ray diffraction (PXRD), proton nuclear magnetic resonance (1H-NMR), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and Fourier-transformed infrared spectroscopy. The present invention is directed in one aspect to the new solid forms of P027 in themselves, regardless of the technique used for their characterization. Therefore, the techniques and results provided herein are not intended to limit the present invention, but to serve as characterization of the same. The skilled person will be able, given the guidance and results described herein, to compare and characterize using the available techniques the different polymorphs and solvates of the compound 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride (P027).
The preparation of solid samples of compound P027 was performed in a set of 40 solvents (table 6). Solvents were selected according to previous experience with the aim to cover a broad range of properties.
TABLE 6
Solvents used in the crystallization screening
with the corresponding codes
Name
Code
Dimethylsulfoxide
DMS
N,N-Dimethylacetamide
DMA
N,N-Dimethylformamide
DMF
Xylene
XIL
Chlorobenzene
CLB
n-Butanol
NBL
Methyl isobutyl ketone
MIC
Isobutyl acetate
AIB
Pyridine
PYR
Toluene
TOL
3-Pentanone
POA
Propyl acetate
APR
Nitromethane
NIM
Dioxane
DIX
Water
H2O
2-Butanol
BUL
n-Heptane
HEP
Dimethylcarbonate
CDM
Triethylamine
TEA
Isopropyl acetate
AIP
Diethoxymethane
DEM
1,2-Dichloroethane
DCE
Isopropanol
IPH
Acetonitrile
ACN
Cyclohexane
CHE
Methyl ethyl ketone
MEC
Butyl amine
BUA
Ethanol
EOH
Ethyl acetate
AET
1,1,1-Trichloroethane
TCE
n-Hexane
HEX
Diisopropyl ether
DIE
Tetrahydrofuran
THF
Methanol
MOH
Chloroform
CLF
Methyl acetate
MAC
Acetone
ACE
Methyl tert-butyl ether
MTE
Dimethoxymethane
DMM
Dichloromethane
DCM
In order to plan the crystallization screening, the solubility of P027 was determined at room temperature in the set of solvents of table 6 using the following methodology (table 7): 10 mg of the delivered sample were suspended at room temperature in 0.2 mL of the corresponding solvent and successive additions (initially 0.2 mL and finally 0.5 mL) of solvent until the solid was completely dissolved or up to a maximum of 8 mL were performed. After each solvent addition the suspension was vigorously stirred for 10-15 minutes and visually inspected to determine if the solid was completely dissolved. Solubility ranges are listed in table 7.
TABLE 7
Solubility of P027 in different solvents at room temperature
Solvent
mg/mL
Chloroform
>50
Dimethylsulfoxide
>50
Dimethylformamide
>50
Dichloromethane
>50
Methanol
>50
Butyl amine
>50
Water
>50
N,N-Dimethylacetamide
25-50
Nitromethane
25-50
Pyridine
25-50
Ethanol
15-25
1,2-Dichloroethane
15-25
Acetonitrile1
10-20
n-Butanol1
5-10
Acetone
4.0-5.0
Isopropanol1
4.0-5.0
2-Butanol1
3-4
Methyl ethyl ketone1
2-4
3-Pentanone2
1-2
Dioxane2
1-2
Dimethylcarbonate2
1-2
Tetrahydrofuran
<1.2
Methyl acetate
<1.2
Isobutyl acetate
<1.2
Propyl acetate
<1.2
Xylene
<1.2
Isopropyl acetate
<1.2
Toluene
<1.2
Ethyl acetate
<1.2
1,1,1-Trichloroethane
<1.2
Methyl isobutyl ketone
<1.2
Methyl tert-butyl ether
<1.2
Dimethoxymethane
<1.2
Cyclohexane
<1.2
Chlorobenzene
<1.2
n-Heptane
<1.2
n-Hexane
<1.2
Diisopropyl ether
<1.2
Triethylamine
<1.2
Diethoxymethane
<1.2
1The solid was dissolved at 60° C. The solution was left at room temperature and no solid was observed.
2The solid was dissolved at 80° C. The solution was left at room temperature and no solid was observed.
The solvents in which P027 was insoluble were used as antisolvents (e.g. those solvents providing a solubility <1.2 mg/mL). For example, n-Heptane (HEP), Methyl tert-butyl ether (MTE) and diisopropyl ether (DIE) were used as antisolvents. The other solvents were used as dissolving solvents in the different crystallization strategies assayed.
In order to cover the broadest crystallization range possible, several crystallization methodologies were employed using the solvents described in table 6. Procedures oriented to obtain the thermodynamically stable phase as well as procedures directed to obtain kinetically favoured phases were used. Moreover, solvent mediated as well as solvent free crystallization procedures were assayed. A list of the crystallization procedures used in this invention is following:
Additionally to the standard crystallization procedures, a new methodology was used applying polymers to induce the crystallization of new solids. As described in the literature, the use of polymers could favour the formation of new crystalline phases (M. Lang et al. J. Am. Chem. Soc., 2002, 124, 14834; C. Price et al. J. Am. Chem. Soc., 2005, 127, 5512.). Moreover the presence of polymers could support the formation of larger single crystals and stabilize the formation of solvates. A series of polymers (see table 8) were added in catalytic amounts to a solution of P027 and crystallized using the following methodologies:
TABLE 8
Polymers used in this invention
Name
Code
Hydroxipropyl methyl cellulose
HPC
Poly(ethylene glycol)
PGY
Polyvinyl pyrrolidone
PVP
Poly(acrylic acid)
PAA
Nylon 6/6
NYL
Polypropylene
PPL
Poly(styrene-co-divinylbenzene)
PSV
Polyvinylchloride
PVC
Poly(tetrafluoroethylene)
PTF
Poly(vinyl acetate)
PVA
Poly(vinyl alcohol)
PVH
Polyacrylamide
PAD
Polysulfone
PLS
Poly(methyl methacrilate methacrylate)
PMM
As used herein referring to polymers, “catalytic amounts” represent a substoichiometric amount of polymer with respect to the compound P027; preferably below a 25% wt of the amount (wt) of compound P027: In a particular embodiment, “catalytic amounts” represent below a 20% wt of the compound P027. In a more particular embodiment, “catalytic amounts” represent below a 10% wt of the compound P027.
All solids obtained using the different crystallization methodologies were characterized by PXRD and classified according to the different PXRD patterns obtained. Further analyses performed were also taken into account for the classification of the solids (see experimental section).
The following forms of P027 were identified and characterized among the solids obtained: P027 phase I form, P027 phase II form, P027 phase III form, P027 phase IV form, P027 dioxane solvate and P027 chloroform solvate.
In one embodiment of the present invention, the P027 phase I form is obtained by dissolving the P027 compound in a suitable solvent and then evaporating the solvent to obtain the phase I crystalline form. According to one variant of this process, the P027 compound is dissolved at a temperature ranging from about room temperature to about 120° C. In another variant to this process, the solvent is evaporated at a temperature ranging from about −21° C. to about 60° C. In a further variant of this process, the P027 solution is allowed to cool down slowly. In yet another variant of this process, the P027 solution is cooled down rapidly.
In another embodiment of the present invention, the P027 phase I form is obtained by mixing a P027 solution and an antisolvent. In a variant of this process, the P027 solution is added to the anti solvent. In another variant of this process, the antisolvent is added to the P027 solution. In an additional variant of this process the P027 solution and the antisolvent are mixed at a temperature ranging from about room temperature to about 90° C.
In an additional embodiment of the present invention, the P027 phase I form is obtained by combining a P027 solution and an antisolvent through diffusion. In a variant of this process, the diffusion is a liquid-liquid diffusion. In another variant of this process, the diffusion is a gas-liquid diffusion.
In another embodiment of the present invention, the P027 phase I form is collected from mixtures of P027, water and solvents.
In yet an additional embodiment of the present invention, the P027 phase I form is obtained from suspensions containing the P027 compound. In variant of this process, the suspension is maintained at a temperature ranging from about room temperature to about 80° C.
In an additional embodiment of the present invention, an hydrochloric acid solution and 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine are mixed to obtain the P027 compound. Preferably, an antisolvent is added to the mixture to induce the crystallization of the P027 compound.
Various of the embodiments above may require additional steps, such as centrifugation, to further isolate the P027 phase I form.
P027 phase II form, phase III form and phase IV form may be obtained in polymer induced crystallizations either by solvent evaporation or by crystallization by antisolvent addition. Thus, another embodiment of the present invention refers to a process for the preparation of polymorphic forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine, comprising:
In a preferred embodiment, P027 phase II form is prepared by evaporation of a solution of P027 in water with the presence of catalytic amounts of poly(vinyl alcohol).
In another preferred embodiment. P027 phase III form is prepared by evaporation of a solution of P027 in water or acetone with the presence of catalytic amounts of poly(ethylene glycol). P027 phase III form may also be conveniently prepared by addition of diisopropyl ether as antisolvent to a solution of P027 in water with the presence of catalytic amounts of poly(ethylene glycol).
In another preferred embodiment, P027 phase IV form is prepared by using chloroform as solvent, diisopropyl ether as antisolvent and the following polymers: polyvinyl pyrrolidone (PVP), poly(acrylic acid) (PAA), polypropylene (PPL), poly(styrene-co-divinylbenzene) (PSV), poly(tetrafluoroethylene) (PTF), poly(vinyl alcohol) (PVH), polyacrylamide (PAD) and poly(methyl methacrilate methacrylate) (PMM).
P027 dioxane solvate may be obtained in a solvent drop grinding experiment in dioxane or by crystallization from a hot saturated solution of dioxane. P027 chloroform solvate may be obtained in polymer induced crystallizations either by solvent (chloroform) evaporation or by crystallization of hot saturated solutions of chloroform.
Thus, another embodiment of the present invention refers to a process for the preparation of solvated forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine, comprising at least one of the 3 alternatives i) to iii):
In a preferred embodiment, P027 dioxane solvate is prepared by:
In a preferred embodiment, P027 chloroform solvate is prepared by:
Another embodiment of the present invention includes the use of crystalline forms phase II, phase III and phase IV of P027 in the obtention of the more stable polymorphic phase I form of P027. In one embodiment, the transformation is by heating of crystalline forms phase II, phase III and phase IV into the polymorphic phase I form.
In the DSC analysis of phases II, III and IV broad exothermic peaks were observed which correspond to a solid-solid transition. The solid-solid transition (recrystallization) of phase II to phase I was observed at 145° C. The solid-solid transition (recrystallization) of phase III into phase I was observed in the range 150-170° C. The solid-solid transition (recrystallization) of phase IV into phase I was observed at 147° C.
Therefore, in another embodiment the invention is directed to the preparation of phase I form of P027 comprising the step of heating crystalline forms phase II, phase III and phase IV of P027 at a temperature between about 140° C. and about 170° C.
Another embodiment of the present invention includes the transformation of a solvate of P027, preferably chloroform solvate, into a more stable polymorphic form such as phase I form. After drying the dioxane solvate for 4 hours at 60° C., 80° C. and 100° C. the transformation to Phase I was observed. The solids obtained were characterized by PXRD.
A further embodiment of the present invention includes pharmaceutical compositions comprising at least one of the forms of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine above-mentioned, particularly P027 phase I, P027 phase II, P027 phase III, P027 phase IV, P027 chloroform solvate and P027 dioxane solvate,
Having described the invention in general terms, it will be more easily understood by reference to the following examples which are presented as an illustration and are not intended to limit the present invention.
a) Powder X-Ray Diffraction Analysis (PXRD)
Approximately 20 mg of the non manipulated samples were prepared in standard sample holders using two foils of polyacetate.
Powder diffraction patterns were acquired on a D8 Advance Series 2Theta/Theta powder diffraction system using CuKα-radiation in transmission geometry (Wavelength: 1.54060). The system was equipped with a V{hacek over (A)}NTEC-1 single photon counting PSD, a Germanium monochromator, a ninety positions auto changer sample stage, fixed divergene slits and radial soller. Programs used: Data collection with DIFFRAC plus XRD Commander V.2.5.1 and evaluation with EVA V.12.0.
b) Proton Nuclear Magnetic Resonance (1H NMR)
Proton nuclear magnetic resonance analyses were recorded in deuterated chloroform (CDCl3) in a Bruker Avance 400 Ultrashield NMR spectrometer, equipped with a z-gradient 5 mm BBO (Broadband Observe) probe with ATM and an automatic BACS-120 autosampler. Spectra were acquired solving 2-10 mg of sample in 0.6 mL of deuterated solvent.
c) Differential Scanning calorimetry Analysis (DSC)
Standard DSC analyses were recorded in a Mettler Toledo DSC822e. Samples of 1-2 mg were weighted into 40 μL aluminium crucibles with a pinhole lid, and were heated, under nitrogen (50 mL/min), from 30 to 300° C. at 10° C./min. Data collection and evaluation was done with software STARe.
d) Thermogravimetric Analysis (TGA)
Thermogravimetric analyses were recorded in a Mettler Toledo SDTA851e. Samples of 3-4 mg were weighted (using a microscale MX5, Mettler) into open 40 μL aluminium crucibles with a pinhole lid, and heated at 10° C./min between 30 and 500° C., under nitrogen (80 mL/min). Data collection and evaluation was done with software STARe.
e) Fourier Transform Infrared Analysis (FTIR)
The FTIR spectra were recorded using a Bruker Tensor 27, equipped with a MKII golden gate single reflection ATR system, a mid-infrared source as the excitation source and a DTGS detector. The spectra were acquired in 32 scans at a resolution of 4 cm−1. No sample preparation was required to perform the analysis.
f) Single Crystal X-Ray Diffraction Analysis (SCXRD)
The measured crystals were selected using a Zeiss stereomicroscope using polarized light and prepared under inert conditions immersed in perfluoropolyether as protecting oil for manipulation. Crystal structure determination was carried out using a Bruker-Nonius diffractometer equipped with a APPEX 2 4K CCD area detector, a FR591 rotating anode with MoKα radiation, Montel mirrors as monochromator and a Kryoflex low temperature device (T=100 K). Fullsphere data collection omega and phi scans. Programs used: Data collection Apex2 V. 1.0-22 (Bruker-Nonius 2004), data reduction Saint+Version 6.22 (Bruker-Nonius 2001) and absorption correction SADABS V. 2.10 (2003). Crystal structure solution was achieved using direct methods as implemented in SHELXTL Version 6.10 (Sheldrick, Universtität Göttingen (Germany), 2000) and visualized using XP program. Missing atoms were subsequently located from difference Fourier synthesis and added to the atom list. Least-squares refinement on F02 using all measured intensities was carried out using the program SHELXTL Version 6.10 (Sheldrick, Universtität Göttingen (Germany), 2000). All non hydrogen atoms were refined including anisotropic displacement parameters.
Initial Synthesis of the P027 Compound
4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride was obtained according to the following protocols:
Between 10 to 20 mg of the P027 compound were dissolved in the minimum amount of the relevant solvents at room temperature (rt), at 60° C. and 80° C. The resulting solutions were left to evaporate rapidly in open vials or slowly in closed tubes pierced with a needle at room temperature (see Tables 9 and 10). Those solutions which were not completely evaporated after 3 months were allowed to evaporate at room temperature in open vials. The solid samples obtained were analyzed by PXRD. The samples showed a pattern consistent with the standard PXRD phase I pattern.
TABLE 9
Fast solvent evaporation at room temperature
Solvent
V (mL)
Dissolution temperature
ACE
2.5
rt
ACN
0.8
60° C.
BUL
3.2
60° C.
CDM
8.0
80° C.
CLF
0.2
rt
DCE
0.6
rt
DCM
0.2
rt
DIX
7.0
80° C.
DMF
0.2
rt
EOH
0.6
rt
H2O
0.2
rt
IPH
2.5
60° C.
MEC
3.5
60° C.
MOH
0.2
rt
NBL
1.4
60° C.
NIM
0.4
rt
PYR
0.4
rt
TABLE 10
Slow solvent evaporation at room temperature
Solvent
V (mL)
Dissolution temperature
ACE
2.5
rt
ACN
0.8
60° C.
CDM
8.0
80° C.
CLF
0.2
rt
DCE
0.6
rt
DCM
0.2
rt
DMF
0.2
rt
EOH
0.6
rt
H2O
0.2
rt
IPH
2.5
60° C.
MEC
3.5
60° C.
NIM
0.4
rt
PYR
0.4
rt
Between 10 to 20 mg of the P027 compound were dissolved in the minimum amount of the relevant solvents at room temperature (rt), at 60° C. or at 80° C. The resulting solutions were left to evaporate, in open vials, at three different temperatures: 60° C., 4° C. and −21° C. (see Tables 11, 12 and 13). Those solutions which were not completely evaporated after 3 months were allowed to evaporate at room temperature in open vials. The solid samples obtained were analyzed by PXRD. The samples showed a pattern consistent with the standard PXRD phase I pattern.
TABLE 11
Solvent evaporation at 60° C.
Solvent
V (mL)
Dissolution temperature
ACE
2.5
rt
ACN
0.8
60° C.
BUL
3.2
60° C.
CDM
8.0
80° C.
CLF
0.2
rt
DCE
0.6
rt
DCM
0.2
rt
DIX
7.0
80° C.
DMA
0.4
rt
DMF
0.2
rt
DMS
0.2
rt
EOH
0.6
rt
H2O
0.2
rt
IPH
2.5
60° C.
MEC
3.5
60° C.
MOH
0.2
rt
NBL
1.4
60° C.
NIM
0.4
rt
POA
6.0
80° C.
PYR
0.4
rt
TABLE 12
Solvent evaporation at 4° C.
Solvent
V (mL)
Dissolution temperature
ACE
2.5
rt
ACN
0.8
60° C.
CLF
0.2
rt
DCE
0.6
rt
DCM
0.2
rt
DIX1
7.0
80° C.
DMF1
0.2
rt
EOH
0.6
rt
IPH
2.5
60° C.
MEC
3.5
60° C.
MOH
0.2
rt
NBL1
1.4
60° C.
NIM
0.4
rt
POA1
6.0
80° C.
PYR
0.4
rt
1The solution was left to evaporate in an open vial at room temperature.
TABLE 13
Solvent evaporation at −21° C.
Solvent
V (mL)
Dissolution temperature
ACE
2.5
rt
ACN
0.8
60° C.
BUL
3.2
60° C.
CLF
0.2
rt
DCE
0.6
rt
DCM
0.2
rt
DMF
0.2
rt
EOH1
0.6
rt
IPH
2.5
60° C.
MEC1
3.5
60° C.
MOH
0.2
rt
NBL
1.4
60° C.
NIM
0.4
rt
PYR1
0.4
rt
1The solution was left to evaporate in an open vial at room temperature.
Between 20 to 30 mg of the P027 compound were dissolved in the minimum amount of the relevant solvents at high temperature to obtain saturated solutions. The solutions were then cooled by two different methods:
After cooling at room temperature the solids obtained were separated by filtration or centrifugation. If no solids were formed, the solution was kept at 4° C. for a few days in first step. Any solids formed during this step were separated from the solution. If no solids were formed during the first step, the solution was kept at −21° C. for a few additional days. Any solids formed during this second step were separated from the solution. The solutions that did not crystallize during the second step were left to evaporate to dryness at room temperature. The solid was filtered off in some experiments when crystallization occurred before complete evaporation.
The solid samples obtained were analyzed by PXRD. The samples showed a pattern consistent with the standard PXRD phase I pattern.
TABLE 14
Slow crystallization from hot saturated solutions
Dissolution
Crystallization
Solvent
V (mL)
temperature
conditions
ACE
3.7
56° C.
at −21° C.
ACN
0.6
80° C.
at rt
BUL
0.4
98° C.
at rt
CLF
0.2
rt
Evaporation
DCE
0.4
80° C.
at rt
DCM
0.4
40° C.
Evaporation
DIX
1.0
101° C.
at rt
DMA
0.2
100° C.
at −21° C.
DMF
0.2
100° C.
Evaporation
EOH
0.4
78° C.
at rt
H2O
0.2
100° C.
Evaporation
IPH
0.6
80° C.
at rt
MEC
2.7
80° C.
at 4° C.
MOH
0.2
56° C.
at −21° C.
NBL
0.4
118° C.
at rt
NIM
0.4
101° C.
at −21° C.
PYR
0.2
rt
Evaporation
TABLE 15
Fast crystallization from hot saturated solutions
Dissolution
Crystallization
Solvent
V (mL)
temperature
conditions
ACE
4.0
56° C.
Immediately
ACN
0.6
80° C.
at −21° C.
BUL
0.4
98° C.
Immediately
CLF
0.2
rt
Evaporation
DCE
0.4
80° C.
at −21° C.
DCM
0.4
40° C.
at −21° C.
DIX
1.0
101° C.
Immediately
DMA
0.2
100° C.
Evaporation
DMF
0.2
100° C.
Evaporation
EOH
0.4
78° C.
at −21° C.
H2O
0.2
rt
Evaporation
IPH
0.6
80° C.
at −21° C.
MEC
2.7
80° C.
at −21° C.
MOH
0.2
56° C.
at −21° C.
NBL
0.4
118° C.
Immediately
NIM
0.4
101° C.
Immediately
PYR
0.2
rt
Immediately
Between 10 to 20 mg of the P027 compound were dissolved in the minimum amount of the relevant dissolving agent at high temperature or at room temperature. Diisopropyl ether (DIE) and n-heptane (HEP) were used as antisolvents. The following protocols were performed:
The solids obtained after mixing the dissolving agent and antisolvent were separated from the solution by filtration or centrifugation. If no solids were formed, the solution was kept at 4° C. for a few days in first step. Any solids formed during this step were separated from the solution. If no solids were formed during the first step, the solution was kept at −21° C. for a few additional days. Any solids formed during this second step were separated from the solution. The solutions that did not crystallize during the second step were left to evaporate to dryness at room temperature. The solid was filtered off in some experiments when crystallization occurred before complete evaporation.
The solid samples obtained were analyzed by PXRD. The samples showed a pattern consistent with the standard PXRD phase I pattern.
TABLE 16
Crystallization by the addition of an antisolvent
to a P027 solution at room temperature
Dissolving
Anti-
Crystallization
Solvent
solvent
conditions
ACE
DIE
at −21° C.
HEP
Evaporation
ACN
DIE
Immediately
HEP1
at 4° C.
BUL
DIE1
Immediately
HEP1
Immediately
CLF
DIE
Immediately
HEP
Immediately
DCE
DIE
Immediately
HEP
Immediately
DCM
DIE
Immediately
HEP
Immediately
DIX
DIE1
Immediately
HEP
Immediately
DMA
DIE
Immediately
HEP1
Evaporation
EOH
DIE
Immediately
HEP
Immediately
IPH
DIE
at 4° C.
HEP
at 4° C.
MEC
DIE
Immediately
HEP
Immediately
MOH
DIE
Immediately
HEP1
Immediately
NBL
DIE
Immediately
HEP1
Immediately
NIM
DIE
Immediately
HEP
Evaporation
PYR
DIE
Immediately
HEP
Immediately
1Solvent and antisolvent were immiscible.
TABLE 17
Crystallization by the addition of an antisolvent
to a P027 solution at high temperature
Dissolving
Anti-
Crystallization
solvent
T (° C.)
solvent
conditions
ACN
65
DIE
Immediately
80
HEP
at −21° C.
BUL
65
DIE
Immediately
90
HEP
Immediately
CLF
60
DIE
Immediately
60
HEP
Immediately
DCE
65
DIE
Immediately
80
HEP
Immediately
DCM
40
DIE
Immediately
40
HEP
Immediately
DIX
65
DIE
Immediately
90
HEP
at −21° C.
DMA
65
DIE
Immediately
90
HEP
Evaporation
EOH
65
DIE
Immediately
75
HEP
Immediately
IPH
65
DIE
at −21° C.
80
HEP
at −21° C.
MEC
65
DIE
Immediately
80
HEP
Immediately
MOH
65
DIE
Immediately
65
HEP
Immediately
NBL
65
DIE
Immediately
90
HEP
Immediately
NIM
65
DIE
Immediately
90
HEP
Evaporation
TABLE 18
Crystallization by the addition of a P027 solution
to an antisolvent at room temperature
Dissolving
Anti-
Crystallization
solvent
solvent
conditions
ACE
DIE
Immediately
HEP
Immediately
ACN
DIE
Immediately
HEP1
Immediately
BUL
DIE
Immediately
HEP
Immediately
CLF
DIE
Immediately
HEP
Immediately
DCE
DIE
Immediately
HEP
Immediately
DCM
DIE
Immediately
HEP
Immediately
DIX
DIE
Immediately
HEP
Immediately
DMA
DIE
Immediately
HEP1
Immediately
EOH
DIE
Immediately
HEP
Immediately
IPH
DIE
Immediately
HEP
Immediately
MEC
DIE
Immediately
HEP
Immediately
MOH
DIE
Immediately
HEP1
Evaporation
NBL
DIE
Immediately
HEP1
Immediately
NIM
DIE
Immediately
HEP1
Evaporation
1Solvent and antisolvent were immiscible.
TABLE 19
Crystallization by the addition of a P027 solution
to an antisolvent at high temperature
Dissolving
Anti-
Crystallization
solvent
T (° C.)
solvent
conditions
ACE
55
DIE
Immediately
55
HEP
Immediately
ACN
65
DIE
Immediately
80
HEP1
at 4° C.
BUL
65
DIE
at 4° C.
90
HEP
Immediately
CLF
60
DIE
Immediately
60
HEP
Immediately
DCE
65
DIE
Immediately
80
HEP
Immediately
DCM
40
DIE
Immediately
40
HEP
Immediately
DMA
65
DIE
Immediately
90
HEP
Immediately
EOH
65
DIE
Immediately
75
HEP
Immediately
IPH
65
DIE
at 4° C.
80
HEP
Immediately
MEC
65
DIE
Immediately
80
HEP
Immediately
MOH
65
DIE
Immediately
65
HEP1
Evaporation
NBL
65
DIE
at 4° C.
90
HEP
Immediately
NIM
65
DIE
Immediately
90
HEP1
Evaporation
1Solvent and antisolvent were immiscible.
133 liters of methyl tert-butyl ether was added to a P027 compound (45 kg) in ethanol (265 l) solution of at T>35° C. Next, the suspension was cooled at 0-5° C. The resulting solid was isolated by centrifugation to yield 40.2 kg of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride.
Between 10 to 50 mg of the P027 compound were dissolved in the minimum amount of the relevant solvents at high temperature or at room temperature. Various dissolving agents were utilized. The following protocols were performed:
The solid samples obtained were analyzed by PXRD. The samples showed a pattern consistent with the standard PXRD phase I pattern.
TABLE 20
Crystallization by liquid-liquid diffusion
Dissolving
V Solvent
Anti-
Crystallization
solvent
(mL)1
solvent
conditions
ACN
0.8
DIE
Crystallization
HEP
Crystallization
CLF
1
DIE
Crystallization
HEP
Crystallization
DCE
1.2
DIE
Crystallization
HEP
Crystallization
DCM
1
DIE
Crystallization
HEP
Crystallization
EOH
1.2
DIE
Crystallization
HEP
Crystallization
IPH
2.5
DIE
Evaporation
HEP
Crystallization
MOH
1
DIE
Evaporation
HEP
Evaporation
NIM
1
DIE
Evaporation
HEP
Evaporation
PYR
1
DIE
Evaporation
HEP
Crystallization
1Equal quantities of dissolving solvent and antisolvent were added.
TABLE 21
Crystallization by gas-liquid diffusion
Dissolving
Anti-
Crystallization
solvent
solvent
conditions
ACN
HEP
Evaporation
DIE
Crystallization
CLF
HEP
Crystallization
DIE
Crystallization
DCE
HEP
Crystallization
DIE
Crystallization
DCM
HEP
Crystallization
DIE
Crystallization
DMF
HEP
Crystallization
DIE
Crystallization
EOH
HEP
Crystallization
DIE
Crystallization
MOH
HEP
Crystallization
DIE
Crystallization
NIM
HEP
Evaporation
DIE
Evaporation
PYR
HEP
Crystallization
DIE
Crystallization
Between 10 to 20 mg of the P027 compound were dissolved in the minimum amount of the relevant solvent saturated with water. The solvents were mixed at various ratios with water according to their miscibility (see Table 22).
The solutions were allowed to crystallize at room temperature in a closed tube for two weeks. If no solids were formed, the solution was kept at 4° C. for a few days. Any solids formed during this step were separated from the solution. If no solids were formed during the first step, the solution was left to evaporate to dryness at room temperature.
The solid samples obtained were analyzed by PXRD. The samples showed a pattern consistent with the standard PXRD phase I pattern.
TABLE 22
Crystallization from mixtures of water and solvent
Dissolution
Water
Solvent
V (mL)
Temperature (° C.)
saturation
Observations
ACN
0.2
60
50%
Evaporation
0.2
60
75%
Evaporation
CLF
0.9
60
0.2%
Evaporation
DCE
0.4
70
0.15%
Evaporation
DCM
0.4
40
0.15%
Evaporation
DIX
0.2
60
50%
Evaporation
0.2
60
75%
Evaporation
IPH
0.2
60
25%
Evaporation
0.2
60
50%
Evaporation
MEC
0.2
60
10%
Evaporation
MOH
0.2
60
25%
Evaporation
NBL
0.2
60
15%
Crystallization
Approximately 40 mg of P027 phase I were transferred to a ball mill container together with catalytic quantities of the relevant solvent (three drops). The P027 phase I and the solvent were grinded at a maximum frequency of 30 s−1 for 30 minutes (see Table 23).
The solid samples obtained were analyzed by PXRD. The samples showed a pattern consistent with the standard PXRD phase I pattern, thus demonstrating that P027 phase I is stable after grinding.
TABLE 23
Solvents utilized in grinding assays
ACE
DCE
EOH
NIM
ACN
DCM
IPH
POA
BUL
DMA
MEC
PYR
CDM
DMF
MOH
THF
CLF
DMS
NBL
Tablets of P027 phase I were prepared in a hydraulic press at three different pressures (5, 7.5 and 10 tons) for three different times (5, 30 and 90 minutes) [see Table 24].
The solid samples obtained were analyzed by PXRD. The samples showed a pattern consistent with the standard PXRD phase I pattern, thus demonstrating that P027 phase I is stable under pressure.
TABLE 24
Pressure parameters
Pressure
Time
(Tons)
(min)
5
5
5
30
5
90
7.5
5
7.5
30
7.5
90
10
5
10
30
10
90
Between 30 to 400 mg of the P027 compound were stirred in 4 mL of the relevant solvent for: i) 48 hours at room temperature or ii) 24 hours at 80° C. (see Table 25).
All suspensions were filtered. The solid samples obtained were analyzed by PXRD. The samples showed a pattern consistent with the standard PXRD phase I pattern.
TABLE 25
Slurry suspensions
Solvent
T (° C.)
DIE
rt
65
HEP
rt
80
TCE
rt
70
The P027 phase I form shows a PXRD pattern having characteristic peaks at a reflection angle [2θ] of about 5.9, 8.1, 11.3, 11.7, 14.2, 15.1, 15.8, 16.3, 16.8, 17.8, 18.1, 18.6, 19.8, 20.9, 21.9, 22.8, 23.0, 23.2, 23.6, 23.9, 24.3, 25.0, 25.1, 28.0, 28.3, 28.6, 29.0, 29.2, 30.7, and 30.9 with the 2θ values being obtained using copper radiation (CuKα1 1.54060 Å).
Differences in the PXRD patterns peak intensities could be observed depending of the crystallization procedure or crystallization solvent used (see
In order to verify if the differences in the peak intensities were due to texture effects, some selected samples were gently grinded in an agate mortar and measured. After homogenizing the samples, the texture effects became less pronounced or disappeared (see
In addition, several samples of phase I were analyzed by 1H NMR in order to check the stability of the salt. The chemical shifts and the integrations of the 1H NMR signals were coincident for all samples and no signs of the lost of HCl or decomposition of the samples could be observed (see
A DSC analysis of phase I samples was performed with a heating rate of 10° C./min. The analysis presented a sharp endothermic peak, which does not recover the base line, with an onset at 194° C. and an enthalpy of 103 J/g corresponding to melting followed by decomposition of the product (see
In a TGA of a phase I sample a weight loss, due to decomposition of the sample, was observed at temperatures higher than 195° C. (see
The FTIR spectrum of P027 phase I presented intense peaks at about 2965, 2609, 1632, 1600, 1559, 1508, 1490, 1439, 1376, 1301, 1257, 1242, 1169, 1129, 1103, 1042, 1010, 932, 914, 862, 828 and 753 cm−1 (see
The identity and crystal structure of the P027 compound phase I was assayed by a single crystal X-ray structure determination. Suitable crystals were obtained by slow diffusion of n-heptane into a concentrated solution of the product in acetone. Since the selected crystals were mostly twinned, a small fragment of a plate (0.30×0.30×0.07 mm3) was separated with a micro scalpel and used for single crystal X-ray structure determination. Table 26 shows the measurement conditions utilized, cell constants and results obtained in a single crystal X-ray structure diffraction analysis. Table 27 depicts phase I selected bond distances and angles for an X-ray structure determination performed at 100 K.
TABLE 26
Phase I single crystal X-ray structure diffraction analysis
Measurement conditions, cell constants and results
Parameter
Value
Empirical formula
C20 H24 Cl1 N3 O2
Formula weight
373.87 UMA
Temperature
100(2) K
Wavelength
0.71073 Å
Crystal system
Monoclinic
Space group
C2/c
Unit cell dimensions
a = 29.367(3) Å, α = 90°
b = 11.6704(11) Å, β = 91.284(2)°
c = 11.0437(10) Å, γ = 90°
Volume
3784.0(6) Å3
Z
8
Density (calculated)
1.313 Mg/m3
Absorption coefficient
0.221 mm−1
F(000)
1584
Crystal size
0.40 × 0.40 × 0.10 mm3
Theta range for data collection
2.64 to 38.06°.
Index ranges
−50 <= h <=50, −20 <= k <=
18, −17 <= l <= 19
Reflections collected
42960
Independent reflections
10292 [R(int) = 0.0414]
Completeness to theta = 38.06°
99.5%
Absorption correction
SADABS (Bruker-Nonius)
Max. and min. transmission
0.9782 and 0.9167
Refinement method
Full-matrix least-squares on F2
Data/restraints/parameters
10292/0/237
Goodness-of-fit on F2
1.043
Final R indices [I > 2sigma(I)]
R1 = 0.0540, wR2 = 0.1409
R indices (all data)
R1 = 0.0733, wR2 = 0.1586
Largest diff. peak and hole
2.152 and −1.013e.Å−3
TABLE 27
Phase I bond lengths [Å] and angles [°]
O(1)—C(1)
1.3601(12)
O(1)—C(15)
1.4357(13)
N(1)—C(3)
1.3545(14)
N(1)—N(2)
1.3774(12)
N(1)—C(4)
1.4271(13)
C(1)—N(2)
1.3290(13)
C(1)—C(2)
1.4056(14)
O(2)—C(18)
1.4184(15)
O(2)—C(19)
1.4339(16)
C(2)—C(3)
1.3802(14)
N(3)—C(16)
1.4995(13)
N(3)—C(20)
1.5028(13)
N(3)—C(17)
1.5055(13)
C(3)—C(14)
1.4887(15)
C(4)—C(5)
1.3749(14)
C(4)—C(13)
1.4156(15)
C(5)—C(6)
1.4192(14)
C(6)—C(7)
1.4228(15)
C(6)—C(11)
1.4277(14)
C(7)—C(8)
1.3749(16)
C(8)—C(9)
1.4141(18)
C(9)—C(10)
1.3770(16)
C(10)—C(11)
1.4211(14)
C(11)—C(12)
1.4225(14)
C(12)—C(13)
1.3755(14)
C(15)—C(16)
1.5063(14)
C(17)—C(18)
1.5157(15)
C(19)—C(20)
1.5127(15)
C(1)—O(1)—C(15)
114.73(8)
C(3)—N(1)—N(2)
112.83(8)
C(3)—N(1)—C(4)
126.90(9)
N(2)—N(1)—C(4)
120.27(8)
N(2)—C(1)—O(1)
122.26(9)
N(2)—C(1)—C(2)
113.61(8)
O(1)—C(1)—C(2)
124.13(9)
C(1)—N(2)—N(1)
102.71(8)
C(18)—O(2)—C(19)
109.40(9)
C(3)—C(2)—C(1)
104.03(9)
C(16)—N(3)—C(20)
113.52(8)
C(16)—N(3)—C(17)
109.85(8)
C(20)—N(3)—C(17)
108.42(8)
N(1)—C(3)—C(2)
106.81(9)
N(1)—C(3)—C(14)
122.28(9)
C(2)—C(3)—C(14)
130.90(10)
C(5)—C(4)—C(13)
121.24(9)
C(5)—C(4)—N(1)
119.67(9)
C(13)—C(4)—N(1)
119.09(9)
C(4)—C(5)—C(6)
120.37(9)
C(5)—C(6)—C(7)
121.81(9)
C(5)—C(6)—C(11)
118.87(9)
C(7)—C(6)—C(11)
119.32(9)
C(8)—C(7)—C(6)
120.56(11)
C(7)—C(8)—C(9)
120.09(11)
C(10)—C(9)—C(8)
120.77(10)
C(9)—C(10)—C(11)
120.51(10)
C(10)—C(11)—C(12)
122.21(9)
C(10)—C(11)—C(6)
118.74(9)
C(12)—C(11)—C(6)
119.05(9)
C(13)—C(12)—C(11)
121.07(9)
C(12)—C(13)—C(4)
119.39(9)
O(1)—C(15)—C(16)
109.35(8)
N(3)—C(16)—C(15)
113.87(8)
N(3)—C(17)—C(18)
109.94(9)
O(2)—C(18)—C(17)
111.58(9)
O(2)—C(19)—C(20)
111.61(10)
N(3)—C(20)—C(19)
109.54(9)
Phase I form crystallizes in the centrosymmetric space C2/c with one cationic molecule and two half independent anionic chlorine atoms in the unit cell (see
The powder diffraction pattern simulated from the single crystal data shows a good correspondence to the experimentally measured standard powder diffraction pattern of phase I. The overlay confirms the phase purity. Small variations in peak positions are due to the temperature difference at which the compared powder diffractograms were measured (simulated at −173° C. and experimentally measured at room temperature).
In the initial screening, a mixture of phase I and a phase II was obtained by solvent evaporation in several solvents (methanol, water, diisopropyl ether-water, nitromethane dioxane-water and heptane-water). This new phase II could be reproduced pure in the screening performed using polymers by evaporation of a solution of P027 in water and with the presence of catalytic amounts of poly(vinyl alcohol).
Crystallization of phase II form by solvent evaporation at room temperature: A Sample of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride (20-25 mg) was dissolved in the minimum amount of water (0.7 ml) at room temperature and a small quantity of poly(vinyl alcohol) (2-3 mg) was added to the corresponding solution. The resulting solution or suspensions was left to evaporate for two weeks in open vials at room temperature.
A comparison of the PXRD patterns of phase I and phase II is shown in
A standard PXRD pattern for phase II form is shown in
Characterization by 1H NMR, DSC and TGA is shown in
The 1H NMR spectrum obtained from the mixture of phases I and II is identical to the one obtained for phase I indicating that phase II is not a decomposition product. The spectra obtained for phase I and phase II are compared in
The DSC analysis of phase II, performed with a heating rate of 10° C./min, shows a weak broad exothermic peak with an onset at 145° C. and an enthalpy of 4 J/g and a sharp endothermic peak with an onset at 194° C. and an enthalpy of 92 J/g, corresponding to melting followed by decomposition of the product (
In the TG analysis of phase II (
Phase III form was generated by polymer induced crystallization. This solid was obtained in four experiments always in the presence of poly(ethylene glycol). In three cases it was obtained by evaporation of water or acetone and in one case it was obtained by addition of diisopropyl ether as antisolvent to a solution in water.
Crystallization of phase form by solvent evaporation at room temperature: A Sample of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride (20-25 mg) was dissolved in the minimum amount of water (0.7 ml) or acetone (5.7 ml) at room temperature and a small quantity of poly(ethylene glycol) (2-3 mg) was added to the corresponding solution. The resulting solution or suspensions was left to evaporate for two weeks in open vials at room temperature.
Crystallization of phase form by addition of an antisolvent: A Sample of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride (20-25 mg) together with poly(ethylene glycol) (3-4 mg) was dissolved in the minimum amount of water at room temperature and diisopropyl ether (10 ml) was added under vigorous stirring. The final suspension was left evaporate.
Phase III was characterized by PXRD, 1H NMR, DSC and TGA. A representative PXRD pattern for phase III is shown in
Characterization by 1H NMR, DSC and TGA is shown in
In the 1H NMR spectrum of phase III the presence of the characteristic signals of P027 indicates that the sample did not decompose. Additionally, in all the spectra measured, the characteristic peak corresponding to poly(ethylene glycol) was observed indicating that phase III is always mixed with this polymer. The 1H NMR spectrum of poly(ethylene glycol) is represented in
The DSC analysis of Phase III (see
In the TG analysis of Phase III (
Phase IV form was only generated by polymer induced crystallization. This phase was formed in experiments performed using chloroform as solvent and diisopropyl ether as antisolvent. Phase IV solid was obtained with the following polymers: polyvinyl pyrrolidone (PVP), poly(acrylic acid) (PAA), polypropylene (PPL), poly(styrene-co-divinylbenzene) (PSV), poly(tetrafluoroethylene) (PTF), poly(vinyl alcohol) (PVH), polyacrylamide (PAD) and poly(methyl methacrilate methacrylate) (PMM). Polymers PVP, PAA, PSV, PVH, PAD and PMM are amorphous and polymers PPL and PTF are crystalline. Only in the sample of phase IV obtained with crystalline PTF, a weak peak of the polymer could be detected in the PXRD pattern.
Crystallization of phase form by addition of an antisolvent: A Sample of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride (20-25 mg) together with 3-4 mg of the corresponding polymer (polyvinyl pyrrolidone, poly(acrylic acid, polypropylene, poly(styrene-co-divinylbenzene, poly(tetrafluoroethylene), poly(vinyl alcohol), polyacrylamide, poly(methyl methacrilate methacrylate)), was dissolved in the minimum amount of chloroform at room temperature and diisopropyl ether (2 ml) was added under vigorous stirring. The final solid obtained was separated by centrifugation.
Phase IV form was characterized by PXRD, NMR, DSC and TGA.
A representative PXRD pattern for Phase IV is shown in
Characterization by 1H NMR, DSC and TGA is shown in
In the 1H NMR spectrum of phase IV (see
The DSC analysis of Phase IV (see
In the TG analysis of Phase IV (
A new crystalline solvated phase, labeled dioxane solvate, was obtained in a solvent drop grinding experiment in dioxane and by crystallization from a hot saturated solution in dioxane. The dioxane solvate crystallizes in form of small sticky crystallites. A representative PXRD pattern of the solvate is shown in
Grinding experiment: 50 mg of compound together with catalytic quantities of dioxane (three drops) were grinded in a ball mill at 30 s−1 for 30 minutes. For the grinding experiments a Retsch MM400 Ball Mill was used.
Crystallization from a hot saturated solution: 0.5 g of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride was dissolved in dioxane (80 mL) at 80° C. The resulting solution was cooled to 40° C. and a solid started to crystallize. The resulting suspension was kept at 40° C. for 2 hours under gentle stirring, cooled to room temperature and kept at that temperature for 2 hours under gentle stirring. The final solid was filtered off.
The DSC analysis of the dioxane solvate, with a heating rate of 10° C./min, presents two overlapped endothermic peaks with onsets at 124° C. and 130° C., probably due to the loss of dioxane, and a third sharp endothermic peak with an onset at 192° C. and an enthalpy of 73 J/g, corresponding to melting followed by decomposition of the product (
In the TG analysis of the dioxane solvate (
The FTIR spectrum characteristic for the dioxane solvate is represented in
The scale-up of the dioxane solvate was performed starting from 50, 100 and 500 mg of the compound. The results obtained in each case are gathered in table 28.
TABLE 28
Scale-up of dioxane solvate
N°
Entry
Scale1
exp.
Procedure
Solvent
Observations
1
50 mg
3
grinding
dioxane
solvate
2
100 mg
1
crystallization
dioxane
solvate
from hot saturated
solution
3
500 mg
3
crystallization
dioxane
solvate
from hot saturated
solution
1Referred to starating compound P027
The solids obtained in the initial screening and in the scale-up at 100 and 500 mg gave the same crystalline phase. At 50 mg scale, the solid was obtained by solvent drop grinding experiments in dioxane. At 100 mg and 500 mg scale, the solid crystallized during cooling to room temperature a hot saturated solution in dioxane.
A new crystalline solvated phase, labeled chloroform solvate, was obtained in polymer induced crystallizations. The chloroform solvate of P027 was obtained by evaporation of a chloroform solution or by crystallization of hot saturated chloroform solutions using the following polymers: poly(ethylene glycol) (PGY), polyvinyl pyrrolidone (PVP), poly (acrylic acid) (PAA), nylon 6/6 (NYL), polypropylene (PPL), poly(tetrafluoroethylene) (PTF), poly(vinyl acetate) (PVA), poly(vinyl alcohol) (PVH), polyacrylamide (PAD) and polysulfone (PLS). The polymers PGY, PPL and PTF are crystalline and the rest amorphous. No signals of the crystalline polymers could be observed in the PXRD patterns. The chloroform solvate crystallizes in the majority of the cases in form of large crystals which are probably stabilized by the presence of the polymers. A representative PXRD pattern of the solvate is shown in
Crystallization of chloroform solvate by solvent evaporation: A Sample of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride (20-25 mg) was dissolved in 0.6 mL of chloroform and 3-4 mg of the corresponding polymer (poly(ethylene glycol), polyvinyl pyrrolidone, poly(acrylic acid), nylon 6/6, polypropylene, poly(tetrafluoroethylene), poly(vinyl acetate), poly(vinyl alcohol), polyacrylamide, polysulfone) was added. The suspension was left to evaporate. After 24 hours, the solid obtained was analyzed by PXRD, DSC and TGA.
The DSC analysis of the chloroform solvate measured with a heating rate of 10° C./min, presents a broad endothermic peak with an onset at 67° C. and an enthalpy of 42 J/g, due to the loss of chloroform, and a second sharp endothermic peak with an onset at 194° C. and an enthalpy of 73 J/g, corresponding to melting followed by decomposition of phase I (
In the TG analysis of the chloroform solvate (
Berenguer Maimó, Ramón, Medrano Rupérez, Jorge, Benet Buchholz, Jordi, Puig Fernandez, Laura, Pellejà Puxeu, Laia
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 7695199, | Jul 20 2006 | II-VI Incorporated; MARLOW INDUSTRIES, INC ; EPIWORKS, INC ; LIGHTSMYTH TECHNOLOGIES, INC ; KAILIGHT PHOTONICS, INC ; COADNA PHOTONICS, INC ; Optium Corporation; Finisar Corporation; II-VI OPTICAL SYSTEMS, INC ; M CUBED TECHNOLOGIES, INC ; II-VI PHOTONICS US , INC ; II-VI DELAWARE, INC; II-VI OPTOELECTRONIC DEVICES, INC ; PHOTOP TECHNOLOGIES, INC | Optical subassembly having insertable cylindrical sleeve |
| 7696199, | Aug 27 2004 | ESTEVE PHARMACEUTICALS, S A | Sigma receptor inhibitors |
| 20080125416, | |||
| EP2113501, | |||
| WO2006021462, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jul 27 2012 | BERENGUER MAIMÓ, RAMÓN | LABORATORIOS DEL DR ESTEVE, S A | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 042638 | /0464 | |
| Jul 27 2012 | BENET BUCHHOLZ, JORDI | LABORATORIOS DEL DR ESTEVE, S A | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 042638 | /0464 | |
| Jul 27 2012 | PUIG FERNANDEZ, LAURA | LABORATORIOS DEL DR ESTEVE, S A | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 042638 | /0464 | |
| Jul 27 2012 | PELLEJÀ PUXEU, LAIA | LABORATORIOS DEL DR ESTEVE, S A | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 042638 | /0464 | |
| Jul 31 2012 | MEDRANO RUPÉREZ, JORGE | LABORATORIOS DEL DR ESTEVE, S A | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 042638 | /0464 | |
| Jun 07 2017 | Laboratorios del Dr. Esteve, S.A. | (assignment on the face of the patent) | / | |||
| Jun 25 2018 | LABORATORIOS DEL DR ESTEVE S A | ESTEVE PHARMACEUTICALS, S A | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 063780 | /0660 |
| Date | Maintenance Fee Events |
| Nov 09 2022 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Date | Maintenance Schedule |
| Jan 29 2022 | 4 years fee payment window open |
| Jul 29 2022 | 6 months grace period start (w surcharge) |
| Jan 29 2023 | patent expiry (for year 4) |
| Jan 29 2025 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jan 29 2026 | 8 years fee payment window open |
| Jul 29 2026 | 6 months grace period start (w surcharge) |
| Jan 29 2027 | patent expiry (for year 8) |
| Jan 29 2029 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jan 29 2030 | 12 years fee payment window open |
| Jul 29 2030 | 6 months grace period start (w surcharge) |
| Jan 29 2031 | patent expiry (for year 12) |
| Jan 29 2033 | 2 years to revive unintentionally abandoned end. (for year 12) |